Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Novel form of vitamin D shown to grow bone


A novel form of vitamin D has been shown to grow bone in the lab and in experimental animals, a result that holds promise for the estimated 44 million Americans, mostly post-menopausal women, who suffer from or are at risk for the bone-wasting disease osteoporosis.

The research, conducted by a team of scientists led by biochemist Hector F. DeLuca at the University of Wisconsin-Madison, was reported this week (Sept. 30) in the Proceedings of the National Academy of Sciences (PNAS), a leading scientific journal.

"We’ve got a compound that is very selective for bone," says DeLuca. "It is very effective in animals," increasing bone density significantly in rats with a condition that mimics human osteoporosis, and can be used in the lab to grow bone in culture.

The research, conducted by DeLuca, Nirupama K. Shevde, Lori A. Plum, Margaret Claggett-Dame, Hironori Yamamoto and J. Wesley Pike, describes the effects of a potent Vitamin D analog known in scientific shorthand as 2MD. Its synthesis by the Wisconsin group, and studies of its effects in the lab and in animals, suggests the potential for developing a class of drugs that could effectively reverse bone loss in humans suffering from osteoporosis, a disease characterized by diminished bone density and, ultimately, brittle, fracture-prone bones.

"From where I sit, this is the most promising vitamin D compound I’ve seen," says DeLuca, an international authority on vitamin D and its chemistry.

But he stressed that while the new compound posts astonishing results when used in experimental animals, it has yet to be tested in humans and it will likely be several years at best before a drug reaches the market.

"There’s nothing like it on the market now. We think it could become a major actor, but we haven’t done any experiments in people," he says.

The compound could become an important alternative to hormone replacement therapy, one of whose benefits was prevention of bone loss in post-menopausal women. Because of new evidence of an increased risk of cancer, hormone replacement therapy has recently been called into question.

The vitamin D analog developed by the Wisconsin team was tested in rats that had their ovaries removed to mimic menopause and the bone wasting associated with osteoporosis. Rats given the new vitamin D analog exhibited a 9 percent increase in total body bone mass. Importantly, vertebrae in the treated rats exhibited a 25 percent increase in bone mass. Frequently, osteoporosis patients exhibit a stooped posture as the bones in the spinal column tend to be among the most affected by osteoporosis.

The compound also added bone mass to the long bones in the limbs of animals used in the study.

According to DeLuca, the 2MD compound is also the first vitamin D analog shown to increase bone mass, and that exhibits no apparent toxicity or side effects.

2MD acts at very low concentrations and appears to work by promoting the growth of osteoblasts, the cells responsible for making bone. Another form of vitamin D is now used to treat osteoporosis, but its bone-building action is limited.

"Our results suggest that 2MD exhibits at very low concentrations a marked and unexpected activity in stimulating the synthesis of new bone," the Wisconsin team wrote in their PNAS report. "This activity is at best only weakly observed with (the other active form of vitamin D) and then only at very high concentrations."

It is possible, the authors suggest, that 2MD possesses a "unique capacity to induce genes capable of orchestrating the process leading to the formation of bone nodules."

Terry Devitt (608) 262-8282,;
Emily Carlson (608) 262-9772, emilycarlson@facstaff

Hector F. DeLuca | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Earlier flowering of modern winter wheat cultivars

20.03.2018 | Agricultural and Forestry Science

Smithsonian researchers name new ocean zone: The rariphotic

20.03.2018 | Life Sciences

Molecular doorstop could be key to new tuberculosis drugs

20.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>